Mankind Pharma Ltd reported a significant growth in Q4 FY24, with a 65.1% increase in net profit to ₹471.2 crore compared to ₹285.4 crore in Q4 FY23. Revenue surged by 19% to ₹2,441.1 crore. EBITDA rose by 41.8% to ₹591.1 crore, with a margin of 24.2%. The company plans to raise ₹7,500 crore via equity shares. Despite positive results, shares closed lower at ₹2,195 on the BSE.
Read More at Cnbctv18
